J. Safra Sarasin Holding Ag Viridian Therapeutics, Inc.\De Transaction History
J. Safra Sarasin Holding Ag
- $5.91 Trillion
- Q4 2024
A detailed history of J. Safra Sarasin Holding Ag transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, J. Safra Sarasin Holding Ag holds 36,453 shares of VRDN stock, worth $572,312. This represents 0.01% of its overall portfolio holdings.
Number of Shares
36,453Holding current value
$572,312% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding VRDN
# of Institutions
200Shares Held
79.4MCall Options Held
477KPut Options Held
917K-
Black Rock Inc. New York, NY4.77MShares$74.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.6MShares$72.1 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.52MShares$71 Million3.82% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$61 Million12.28% of portfolio
-
State Street Corp Boston, MA3.52MShares$55.3 Million0.0% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $626M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...